A review highlighting the need to improve vitiligo care through understanding the role of the JAK-STAT pathway, early diagnosis ...

"Notably, the study found that the thresholds for meaningful change are lower than those typically established in clinical ...

Ensuring that these patient-centred improvements are integrated into trial endpoints helps align clinical outcomes with ...

A few days ago, millions around the world cheered when the US Food and Drug Administration (FDA) approved a treatment for vitiligo - a topical cream that can restore pigment with unprecedented ...

CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) selected Belle.ai as one of six inaugural participants in the first quarterly CMS Artificial ...

Seemal Desai, M.D., FAAD, discusses how immune system dysregulation and genetic variants intersect to trigger vitiligo development while highlighting diagnostic challenges including identifying ...

Investigators conducted a systemic review to summarize evidence regarding the use systemic Janus kinase inhibitors in patients with refractory nonsegmental vitiligo.

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for ...

Research into vitiligo could lead to new treatment options within the next few years, a dermatologist involved in the study ...

China Medical System Holdings has announced the approval of its ruxolitinib phosphate cream for treating non-segmental vitiligo in Hong Kong. This novel treatment offers a new option for the ...